Agnete Fredriksen, Ph.D.Member of the Board of Directors

Agnete Fredriksen, Ph.D., is a co-Founder, Chief Scientific Officer and Business Development of Nykode Therapeutics AS (formerly Vaccibody AS) since April 2024. Before, she was Chief Business Officer from August 2022 to March 2024, Chief Innovation and Strategy Officer June 2021 to July 2022 and President and Chief Scientific Officer from 2017 to June 2021. Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for cancer, autoimmune and infectious diseases. Prior to founding Vaccibody, Dr. Fredriksen previously held research roles at Affitech AS, a private technology transfer company, and Medinnova AS, a technology transfer company. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. She holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, Norway.